Brian M. Hahn - 21 Jan 2022 Form 4 Insider Report for GLYCOMIMETICS INC (GLYC)

Role: SVP Finance, CFO
Signature: /s/ Brian F. Leaf, attorney-in-fact
Issuer symbol: GLYC
Transactions as of: 21 Jan 2022
Net transactions value: $0
Form type: 4
Filing time: 25 Jan 2022, 19:59:24 UTC
Next filing: 10 Mar 2022
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	GLYC	Employee Stock Option (right to buy)	Award	$0	+164,700		$0.000000	164,700	21 Jan 2022	Common Stock	164,700	$1.11	Direct	F1
transaction	GLYC	Employee Stock Option (right to buy)	Award	$0	+47,700		$0.000000	47,700	21 Jan 2022	Common Stock	47,700	$1.11	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	25% of the shares underlying this option will vest on January 21, 2023 and the remaining underlying shares will vest in equal monthly installments over 36 months thereafter, subject to the Reporting Person's continued service with the Issuer through each such vesting date.
F2	50% of the shares underlying this option will vest upon FDA approval of the Issuer's product candidate uproleselan as a treatment for relapsed/refractory acute myeloid leukemia and the remainder will vest upon the first commercial sale of uproleselan in the United States or abroad, subject in each case to the Reporting Person's continued service with the Issuer through the applicable vesting date.

Content

25% of the shares underlying this option will vest on January 21, 2023 and the remaining underlying shares will vest in equal monthly installments over 36 months thereafter, subject to the Reporting Person's continued service with the Issuer through each such vesting date.

50% of the shares underlying this option will vest upon FDA approval of the Issuer's product candidate uproleselan as a treatment for relapsed/refractory acute myeloid leukemia and the remainder will vest upon the first commercial sale of uproleselan in the United States or abroad, subject in each case to the Reporting Person's continued service with the Issuer through the applicable vesting date.